BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33768215)

  • 1. A Protocol for the Generation of Treatment-naïve Biopsy-derived Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma Models.
    Biery MC; Noll A; Myers C; Morris SM; Winter CA; Pakiam F; Cole BL; Browd SR; Olson JM; Vitanza NA
    J Exp Neurol; 2020 Dec; 1(4):158-167. PubMed ID: 33768215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials.
    Vitanza NA; Monje M
    Curr Treat Options Neurol; 2019 Jul; 21(8):37. PubMed ID: 31290035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care.
    Williams JR; Young CC; Vitanza NA; McGrath M; Feroze AH; Browd SR; Hauptman JS
    Neurosurg Focus; 2020 Jan; 48(1):E4. PubMed ID: 31896081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG.
    Chiang J; Diaz AK; Makepeace L; Li X; Han Y; Li Y; Klimo P; Boop FA; Baker SJ; Gajjar A; Merchant TE; Ellison DW; Broniscer A; Patay Z; Tinkle CL
    Acta Neuropathol Commun; 2020 Apr; 8(1):57. PubMed ID: 32326973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
    Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
    Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
    Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
    Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
    Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
    Pachocki CJ; Hol EM
    J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Low-grade glioma with
    Bernstock JD; Karandikar PV; Chen JA; Seidlitz J; Friedman GK; Meredith DM; Liu KX; Haas-Kogan D; Reardon DA; Peruzzi PP
    Front Surg; 2024; 11():1356660. PubMed ID: 38840975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse Intrinsic Pontine Glioma: Molecular Landscape, Evolving Treatment Strategies and Emerging Clinical Trials.
    Damodharan S; Lara-Velazquez M; Williamsen BC; Helgager J; Dey M
    J Pers Med; 2022 May; 12(5):. PubMed ID: 35629262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).
    Gwak HS; Park HJ
    Crit Rev Oncol Hematol; 2017 Dec; 120():111-119. PubMed ID: 29198324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma.
    Misuraca KL; Cordero FJ; Becher OJ
    Front Oncol; 2015; 5():172. PubMed ID: 26258075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
    Mueller T; Laternser S; Guerreiro Stücklin AS; Gerber NU; Mourabit S; Rizo M; Rushing EJ; Kottke R; Grotzer M; Krayenbühl N; Nazarian J; Mueller S
    Eur J Cancer; 2023 Jan; 178():171-179. PubMed ID: 36455411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretation of magnetic resonance images in diffuse intrinsic pontine glioma: a survey of pediatric neurosurgeons.
    Hankinson TC; Campagna EJ; Foreman NK; Handler MH
    J Neurosurg Pediatr; 2011 Jul; 8(1):97-102. PubMed ID: 21721895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic and Metabolic Changes in Diffuse Intrinsic Pontine Glioma.
    Park J; Chung C
    Brain Tumor Res Treat; 2023 Apr; 11(2):86-93. PubMed ID: 37151150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
    Hall MD; Odia Y; Allen JE; Tarapore R; Khatib Z; Niazi TN; Daghistani D; Schalop L; Chi AS; Oster W; Mehta MP
    J Neurosurg Pediatr; 2019 Apr; 23(6):719-725. PubMed ID: 30952114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
    Gardner SL; Tarapore RS; Allen J; McGovern SL; Zaky W; Odia Y; Daghistani D; Diaz Z; Hall MD; Khatib Z; Koschmann C; Cantor E; Kurokawa R; MacDonald TJ; Aguilera D; Vitanza NA; Mueller S; Kline C; Lu G; Allen JE; Khatua S
    Neurooncol Adv; 2022; 4(1):vdac143. PubMed ID: 36382108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.